Gordon Phillips to Maximum Tolerated Dose
This is a "connection" page, showing publications Gordon Phillips has written about Maximum Tolerated Dose.
Connection Strength
0.244
-
Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikharuddin JJ, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, Jordan CT, Phillips GL. A phase I study of decitabine and rapamycin in relapsed/refractory AML. Leuk Res. 2013 Dec; 37(12):1622-7.
Score: 0.101
-
Phillips GL, Bernstein SH, Liesveld JL, Abboud CN, Becker MW, Constine LS, Ifthikharuddin JJ, Loughner JE, Milner LA, Vesole DH, Friedberg JW. A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. Biol Blood Marrow Transplant. 2011 Jul; 17(7):1033-42.
Score: 0.083
-
Hari P, Reece DE, Randhawa J, Flomenberg N, Howard DS, Badros AZ, Rapoport AP, Meisenberg BR, Filicko-Ohara J, Phillips GL, Vesole DH. Final outcomes of escalated melphalan 280?mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival. Bone Marrow Transplant. 2019 02; 54(2):293-299.
Score: 0.035
-
Howard DS, Liesveld J, Phillips GL, Hayslip J, Weiss H, Jordan CT, Guzman ML. A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia. Leuk Res. 2013 Nov; 37(11):1502-8.
Score: 0.025